Pharmaceutical Executive, September 2019 Issue (PDF)

EVERSANA's Jen Norton talks about how AI is reshaping market access strategy, a new analysis from MIT and Harvard Business School names clinical data harmonization as the real barrier to enterprise AI adoption in life sciences, and Novo Nordisk's CEO says he's open to a direct NYSE listing.

Novo Nordisk CEO Mike Doustdar says he's open to a direct NYSE listing that would replace the company's ADR structure.

Market access is now too complex for historical analogues — and AI is the only tool that can model what comes next.

Clinical data harmonization is the real bottleneck standing between life sciences companies and AI's transformative potential.

Inovalon's Jen Lamppa on why AI's ability to extract insights from unstructured clinical data is foundational to making RWD usable in trials.

Nine major European drugmakers warn the region risks losing pharma investment, Novartis licenses a preclinical radioligand therapy asset from BoomRay Pharmaceuticals, and Rafaat Rahmani argues that the costliest competitive intelligence failure is missing the moment a strategic assumption goes wrong.

The best CI partner isn't the one with the most data — it's the one willing to tell you your assumptions are wrong.

Chairs of Europe's largest drugmakers urge the EU to boost health spending, speed up clinical trials, and strengthen IP protections before falling further behind the US and China.